227 related articles for article (PubMed ID: 15496647)
21. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial.
Coppola G; Franzoni E; Verrotti A; Garone C; Sarajlija J; Operto FF; Pascotto A
Brain Dev; 2007 Jun; 29(5):281-4. PubMed ID: 17055681
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy.
Yu Y; Zhang Q; Xu W; Lv C; Hao G
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):345-51. PubMed ID: 25700977
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment.
Friis ML; Kristensen O; Boas J; Dalby M; Deth SH; Gram L; Mikkelsen M; Pedersen B; Sabers A; Worm-Petersen J
Acta Neurol Scand; 1993 Mar; 87(3):224-7. PubMed ID: 8475694
[TBL] [Abstract][Full Text] [Related]
24. The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study.
Wegner I; Wilhelm AJ; Sander JW; Lindhout D
Epilepsy Behav; 2013 Oct; 29(1):217-21. PubMed ID: 23995050
[TBL] [Abstract][Full Text] [Related]
25. Overnight transition from carbamazepine to oxcarbazepine in children and adolescents.
Vaisleib II; Neft RA
Pharmacotherapy; 2008 Oct; 28(10):1211-4. PubMed ID: 18823216
[TBL] [Abstract][Full Text] [Related]
26. Oxcarbazepine and adverse events: impact of age, dosage, metabolite serum concentrations and concomitant antiepileptic therapy.
Ortenzi A; Paggi A; Foschi N; Sabbatini D; Pistoli E
Funct Neurol; 2008; 23(2):97-100. PubMed ID: 18671911
[TBL] [Abstract][Full Text] [Related]
27. Oxcarbazepine monotherapy in children and adolescents: a single-center clinical experience.
Kothare SV; Khurana DS; Mostofi N; Melvin JJ; Marks HG; Valencia I; Legido A
Pediatr Neurol; 2006 Oct; 35(4):235-9. PubMed ID: 16996394
[TBL] [Abstract][Full Text] [Related]
28. Concomitant administration of rifampicin and oxcarbazepine results in a significant decrease of the active MHD metabolite of oxcarbazepine.
Sigaroudi A; Kullak-Ublick GA; Weiler S
Eur J Clin Pharmacol; 2016 Mar; 72(3):377-8. PubMed ID: 26631062
[No Abstract] [Full Text] [Related]
29. Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability.
Gaily E; Granström ML; Liukkonen E
J Intellect Disabil Res; 1998 Dec; 42 Suppl 1():41-5. PubMed ID: 10030431
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of oxcarbazepine in the dog.
Schicht S; Wigger D; Frey HH
J Vet Pharmacol Ther; 1996 Feb; 19(1):27-31. PubMed ID: 8992022
[TBL] [Abstract][Full Text] [Related]
31. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium.
Mazzucchelli I; Onat FY; Ozkara C; Atakli D; Specchio LM; Neve AL; Gatti G; Perucca E
Epilepsia; 2006 Mar; 47(3):504-9. PubMed ID: 16529613
[TBL] [Abstract][Full Text] [Related]
32. Clinical pharmacokinetics of oxcarbazepine.
May TW; Korn-Merker E; Rambeck B
Clin Pharmacokinet; 2003; 42(12):1023-42. PubMed ID: 12959634
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.
Lin WW; Li XW; Jiao Z; Zhang J; Rao X; Zeng DY; Lin XH; Wang CL
Eur J Clin Pharmacol; 2019 Mar; 75(3):381-392. PubMed ID: 30456415
[TBL] [Abstract][Full Text] [Related]
34. Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate.
Fountain NB; Conry JA; Rodríguez-Leyva I; Gutierrez-Moctezuma J; Salas E; Coupez R; Stockis A; Lu ZS
Epilepsy Res; 2007 Apr; 74(1):60-9. PubMed ID: 17270398
[TBL] [Abstract][Full Text] [Related]
35. Assessment of the bioequivalence of two oxcarbazepine oral suspensions versus a film-coated tablet in healthy subjects.
Flesch G; Tudor D; Denouel J; Bonner J; Camisasca R
Int J Clin Pharmacol Ther; 2003 Jul; 41(7):299-308. PubMed ID: 12875346
[TBL] [Abstract][Full Text] [Related]
36. Amelioration of erectile dysfunction following a switch from carbamazepine to oxcarbazepine: recent clinical experience.
Sachdeo R; Sathyan RR
Curr Med Res Opin; 2005 Jul; 21(7):1065-8. PubMed ID: 16004674
[TBL] [Abstract][Full Text] [Related]
37. Safety and tolerability of oxcarbazepine in elderly patients with epilepsy.
Kutluay E; McCague K; D'Souza J; Beydoun A
Epilepsy Behav; 2003 Apr; 4(2):175-80. PubMed ID: 12697143
[TBL] [Abstract][Full Text] [Related]
38. Topiramate pharmacokinetics in children with epilepsy aged from 6 months to 4 years.
Mikaeloff Y; Rey E; Soufflet C; d'Athis P; Echenne B; Vallée L; Bouhours P; Grinspan A; Dulac O; Pons G; Chiron C
Epilepsia; 2004 Nov; 45(11):1448-52. PubMed ID: 15509246
[TBL] [Abstract][Full Text] [Related]
39. Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans.
Almeida L; Soares-da-Silva P
Drugs R D; 2003; 4(5):269-84. PubMed ID: 12952496
[TBL] [Abstract][Full Text] [Related]
40. Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans.
Almeida L; Soares-da-Silva P
J Clin Pharmacol; 2004 Aug; 44(8):906-18. PubMed ID: 15286095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
